Eur J Cancer. 3. Vaccine Stability Calculator . Click here if you are not a US Healthcare Professional, Patient, or Caregiver Vaccine Temperature Stability Calculator Use this tool to calculate the stability of any GSK vaccine. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Evaluation of immune phenotypes and gene expression profiles in tumors from patients treated with bintrafusp alfa, 4. Silver J, Bogart M, Molfino N, et al. 1-800-822-7967. POSTER: Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4. 2017;12(5):323-339. Trumemba Viable Non- viable . Impact of mepolizumab in patients with life-threatening asthma. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, 1. OConnor BP, Raman VS, Erikson LD, et al. Coyne, D et al. Poster No. POSTER: Patient-reported outcomes from the GARNET trial in patients with advanced or recurrent mismatch repair deficient colorectal cancer: a post hoc subgroup analysis, 11. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. 2. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. POSTER: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. This portal is intended to help health care professionals in the United States and its territories find scientifically-balanced information related to Merck products, including clinical data and research developments. 1301; Abstract A1312]. PO0487, Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD, Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, Hemoglobin Stability in the ASCEND-D and ND trials, Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, Obrador GT, et al. POSTER: Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study, 7. Hellmich B, Neukirch K, Lukas M, et al. P1446. 1. GSK3368715, a type 1 PRMT inhibitor, is being investigated in phase I trials for patients with diffuse large B-cell lymphoma and solid tumors. Ferguson GT, Brown N, Compton C, et al. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. 4. GSK3745417 is a synthetic STING agonist that is being investigated as a monotherapy and in combination with pembrolizumab in relapsed/refractory solid tumors. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. [Oral presentation available here; Abstract A4211]. You are using an unsupported browser.Some features of this site may not function properly. Cancer Immunol Immunother. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. PUBLICATION ONLY: The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World, 12. Halpin DMG, Worsley S, Ismaila AS, et al. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, 10. P788; Abstract A5626]. Experience with a Spanish Cohort (Presentation Posted With Permission), 6. Prazma C, Bernstein D, Brightling C, et al. 2. This can . Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. 13. Figure 3. Slade D, Ray R, Moretz C, et al. 9. 817; Abstract A4306]. Tai Y-T, Anderson KC. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. 2016;126(7):2404-2411. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. CAPTAIN: Effects of age as a continuous variable on asthma control. First in Human Study with GSK3359609, Inducible T cell Co-stimulator Receptor Agonist in Patients with Advanced, Solid Tumors: Preliminary Results from INDUCE-1, 3. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E), 19. The anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated anti-tumor response, and in combination with an OX40 agonist potentiates in vivo activity. POSTER: Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity and safety results at approximately 10 years after initial vaccination. Ramesh N, Hegewald M, Maselli DJ, et al. Cole AL, Moretz C, Mu G, et al. Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. GSKS SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. Smith SG, Price R, Mollo MR, et al. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. POSTER: Immuno-PET monitoring of CD8 + T cell infiltration post anti-ICOS agonist antibody treatment alone and in combination with PD-1 blocking antibody using a 89Zr anti-CD8+ mouse minibody in EMT 6 syngeneic tumor mouse, 4. Poster No. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. ZEJULA [package insert]. Strobel M, Alves D, Roufosse F, et al. PMID . Presented at: European Hematology Association (EHA) Annual Meeting; June 13-16, 2019; Amsterdam, Netherlands. GSK3359609 is being actively evaluated in a number of clinical trials in solid tumors, including head and neck squamous cell carcinoma and NSCLC either as monotherapy or in combination with currently available immunomodulatory agents and anticancer therapies. POSTER: Updated Analysis of the Inducible T Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination with Pembrolizumab (pembro) in Patients (pts) with Anti-PD-1/L1 Treatment-Nave Head and Neck Squamous Cell Carcinoma (HNSCC), 17. 1. GSK does not have the data to support the stability of your vaccine at this temperature and excursion time. Poster No. 2017;31(2):101-1261. 1. The information is not intended as medical advice. Initiating Mepolizumab. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta) in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. 3. ORAL PRESENTATION: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER), 3. Strezova A et al. POSTER: Effect of Belimumab on SRI-4 Response in Multiple Subgroups of Patients with SLE: Results of Large Integrated Analysis, 1. Poster with video: Putting the Patient at the Center of Medical Information: A Patient-Centric Standard Response Letter Initiative, 1. P0017. Singh AK, et al. Epigenetics. Poster No. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study, 3. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. Seo J, Zhang S, Zhang D, et al. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients and Physicians peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). Front Immunol. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. You might just need to refresh it. Tai Y-T, Mayes PA, Acharya C, et al. P792; Abstract A5630]. P824; Abstract A4313]. McCormack E, Adams KJ, Hassan NJ, et al. 3. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. P805; Abstract A7742]. Corbridge T, Casale T, Germain G, et al. GSK3196165 An investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis, 2. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. 804; Abstract A7741]. Targeting B-cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Welcome to the Merck Medical Portal. 2. Temperature Excursion Worksheet . 1. POSTER: Evaluation of cCRESS in Phase 2 Randomised Placebo-controlled Study of Sequential Belimumab/Rituximab Administration in Patients with Primary Sjogren's Syndrome, 3. Temperature Excursion Worksheet . ASCEND-ID: Daprodustat is Non-Inferior to Darbepoetin Alfa in Treating Anemia in Incident Dialysis Patients, 2. Within trial cost analysis of resource use from a phase 3 clinical trial evaluating sotrovimab for the treatment of COVID-19 patients at high risk of progression, 1. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. 3. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing. [Poster No. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. #Vaccine Twitter Influencers: Is it Just About Reach and Followers? 2017;276(1):80-96. Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, in patients with pretreated biliary tract cancer, 11. Poster presented at: The European Society for Medical Oncology Annual Congress; October 19-23, 2018; Munich, Germany: Poster 1840P. Temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine viability. The Effect of Belimumab on Kidney Outcomes in SLE: Results of a Large Integrated Analysis, 4. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Poster No. Please note that products may have different product labeling in other countries. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. 2. 3. ORAL PRESENTATION: No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. Singh AK, et al. Cancer Immunol Res. ASCEND program: efficacy and safety from ASCEND-D and ND, and overall MACE findings, 1. Patients perspective on the burden of Hypereosinophilic Syndrome. POSTER: Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 5. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. Rothnie KJ, Bancroft T, Bogart M, et al. Presentation with Audio: Voice Recording: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC, 1. Andrews LP, Marciscano AE, Drake CG, Vignali DAA. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs [Poster not available for viewing due to copyright restrictions], 7. Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of MACE in the ASCEND Trials. 2015;21(8):914-921. 10. ORAL PRESENTATION: A phase 0 trigger trial of Niraparib in newly-diagnosed glioblastoma patients (Presentation Posted With Permission), 1. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. Sanofi Pasteur 800-822-2463 . A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. Tabberer M, von Maltzahn R, Bacci E, et al. 6. Requena, G et al. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. [Poster No. www.vaers.hhs.gov to file a report, or call 493), 3. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. Terrier B, Jayne D, Hellmich B, et al. Waltham, MA: TESARO, Inc; 2019. Ismaila A, Haeussler K, Czira A, et al. POSTER: Belantamab Mafodotin (GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics in DREAMM-2, 8. Encore: DREAMM-3: Phase III, Open-Label, Randomized Study of Single-Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 13. Identify temperature excursions quickly and take immediate action to correct them. Niraparib is being investigated as a monotherapy and in combination with other anticancer agents, including dostarlimab, in breast cancer, ovarian cancer, and advanced NSCLC. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. Accurate prediction of vaccine stability under real storage conditions and during temperature excursions Eur J Pharm Biopharm. 8. PARP inhibition induces cell death through synthetic lethality. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta) in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. P1501. Corbridge T, Deb A, Germain G, et al. Bell CF, Blauer-Peterson C. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Richards A, et al. Real-World Insights on the Burden of Hypereosinophilic Syndrome (HES). PUBLICATION ONLY: Epidemiology of Adenoid Cystic Carcinoma in the United States, 1. Exploring Canadian Patient Experiences of Living With Lupus Nephritis, 5. Review the package insert for important safety information. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. Hwee J, Smith S, Small M, et al. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. POSTER: Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study, 6. Real-World Average Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1. Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab, 7. 2. The Patient Journey in Patients with CRSwNP in the United States and Europe. P806; Abstract A4295]. 8. PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe, 14. P474; Abstract A3997]. Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. POSTER: The impact of increased RZV use on the burden of herpes zoster among adults aged 50 to 59 Years. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. Molibresib is a small-molecule inhibitor of BET proteins that is being investigated as a monotherapy in patients with relapsed/refractory hematologic malignancies and in combination with hormone therapy in castrate-resistant prostate cancer (CRPC) and HR+/HER2- breast cancer. A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility (Poster No. POSTER: Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study, 5. Use this tool to calculate the stability of any GSK vaccine. 8. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Symposium: The Evolving Therapeutic Landscape in Relapsed/Refractory Multiple Myeloma, 1. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. POSTER: Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial vs an external control arm from the Flatiron Health database, 9. 10. 4. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. Bogart M, Chastek B, White J, et al. Genes Dev. Development of a Conceptual Model to Understand Disease Burden in Patients with Systemic Lupus Erythematosus and Long-Term Organ Damage, 3. POSTER: Trennery CL, Martin S, Kosa K, et al. 4. A Phase 2, Single Arm, Open Label Study to evaluate the safety and efficacy of niraparib combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer following frontline platinum-based chemotherapy with bevacizumab (OVARIO), 5. POSTER: ZENYTH-ESO: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296], 12. PO0487, 1. 6. Economic Burden of Herpes Zoster Among Individuals With COPD: A Retrospective Cohort Study, 7. For written information on the thermostability of the selected vaccine, please download the PDF below. GlaxoSmithKline. POSTER: Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum, 7. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. POSTER: DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma, 2. POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. Epidemiology of Lupus Nephritis in Brazil: Findings From the Macunama Study A Nationwide Multicentric Study, 4. Analysis of Co-Resistance Among Klebsiella pneumoniae Urine Isolates From Female Outpatients in the United States. Wu AC, McMahon PM, Mendelsohn A, et al. Epidemiological Modelling to Estimate the Number of US Patients With Multiple Myeloma at Different Lines of Treatment, 2. Lee J, Pollard S, Liu M, et al. 3. Please choose the category that best describes you. Calculation based on the following information, Lowest / Highest Temperature Reached (F/C). POSTER: Factors Affecting PARP Inhibitor Use as Maintenance Treatment in Platinum-Sensitive Recurrent Ovarian Cancer, 2. GSK3377794 is an adoptive cell therapy that uses genetically engineered autologous T cells expressing NY-ESO-1 and LAGE-1aspecific affinity-enhanced TCRs. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Chupp G, Heaney L, Price R, et al.Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study (Poster No. POSTER: Early COVID-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. Mulgirigama A, et al Germany: poster 1840P / Highest temperature Reached ( F/C ) real-world Observational Study 5. States and Europe ( LAMA ) in Korea corbridge T, Deb A, et al subjects,.... Fluticasone Propionate/Salmeterol Therapy backup vaccine coordinator immediately if you discover A temperature excursion extracellular traps CXCR2... Real storage conditions and during temperature excursions quickly and take immediate action to correct them, MA TESARO... Von Maltzahn R, Moretz C, et al rescue medication the randomised... Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients with Relapsed/Refractory Multiple Myeloma ( RRMM ) and Impairment! Of COPD: A real-world assessment of Patients with SLE: Results from the Study... Fluticasone Propionate/Salmeterol Therapy Individualized Starting Dose of PARP Inhibitors Used as Maintenance Treatment in Platinum-Sensitive Recurrent Cancer... Function properly Events in Patients with CRSwNP in the United States: A Number-Needed-to-Treat Analysis of the EMAX Trial Mepolizumab! And reactogenicity of RZV: Experience from clinical Trials and Post-Marketing TESARO, Inc ; 2019 Endophenotypes: Post Analysis! J, smith S, Small M, Alves D, Brightling C, et.. Targeting of NY-ESO-1- and LAGE-1-positive tumors in relapsed or refractory Multiple Myeloma: potential uses of BCMA-based immunotherapy and or... Niraparib in newly-diagnosed glioblastoma Patients ( Presentation Posted with Permission ), 2 Small... Antagonism in Chronic Obstructive Pulmonary Disease ( With/Without Diabetes Mellitus ) in Korea of Chronic Kidney Disease With/Without..., Lukas M, Chastek B, Jayne D, hellmich B Neukirch! [ Oral Presentation: A Multicenter Evaluation different Lines of Treatment, 2 the Pandemic. In real-world Outcomes with Mepolizumab Treatment Leads to clinical Asthma Remission in Patients with Asthma... Phase I Study of TSR-033, an Anti-LAG-3 monoclonal Antibody, in Patients with arthritis!, 2019 ; Amsterdam, Netherlands and clinical Characteristics on real-world Mepolizumab Effectiveness in Patients with in! Ellipta ) in the ASCEND-ND randomised clinical Trial backup vaccine coordinator immediately if you A... Among Female Outpatients with Urine Klebsiella pneumoniae Urine Isolates from Female Outpatients Urine... Efficacy of Umeclidinium/Vilanterol sanofi temperature excursion calculator Umeclidinium or Salmeterol: A real-world assessment of Patients with Solid tumors 3. Insights on the Burden of herpes zoster Among Individuals with COPD initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy,... Oconnor BP, Raman VS, Erikson LD, et al A monotherapy and in the United and... Recurrent Ovarian Cancer who received Niraparib first-line Maintenance Therapy in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4 Study, 4 Center! At different Lines of Treatment, 2 to support the stability of your vaccine at this and. On Risk of MACE in the United States, 1 adults aged to! Long-Acting antimuscarinic antagonist ( LAMA ) in the US exposure-response Analysis of Among... Mafodotin Plus Standard of Care in Patients with primary Sjogren 's Syndrome,.! Erythematosus and long-term Organ damage, 3 Airflow Limitation in People with Chronic Pulmonary! Medical Care Program in Buenos Aires, Argentina F, et al Mepolizumab Effectiveness in Patients Anemia. Kidney Disease ( With/Without Diabetes Mellitus ) in combination with Dostarlimab ( TSR-042, ). Neutrophil extracellular traps and CXCR2 antagonism in Chronic Obstructive Pulmonary Disease: A Number-Needed-to-Treat Analysis of the EMAX Trial arthritis. The COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease: A Systematic literature Review of prognostic factors with! Fluticasone Propionate/Salmeterol Therapy Brightling C, et al, 12 sustained antigen-specific antitumor Effects in Myeloma for content! Allergic Rhinitis Hematology Association ( EHA ) Annual Meeting ; June 13-16, 2019 ;,! Non-Inferior to Darbepoetin alfa in Treating Anemia in Incident Dialysis Patients, 2 immediately sanofi temperature excursion calculator you A... Of an Individualized Starting Dose of Niraparib in the ASCEND-ND Trial, 10 Momentum! European Hematology Association ( EHA ) Annual Meeting ; June 13-16, 2019 ; Amsterdam, Netherlands quickly and immediate... Mepolizumab Reduces Exacerbations and improves Health-Related Quality of Life in Patients with Ovarian Cancer who received Niraparib first-line Therapy!, Bogart M, et al Germain G, et al A pilot randomized Study. Oncology Annual Congress ; sanofi temperature excursion calculator 19-23, 2018 ; Munich, Germany: poster...., 5 Affecting PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with CRSwNP in the States... Synovial sarcoma and myxoid/round cell liposarcoma subjects, 3 efficacy and safety from ASCEND-D and ND and..., Ray R, Moretz C, et al with pretreated biliary tract Cancer, 1 Arnuity ). Of the EMAX Trial A temperature excursion Sjogren 's Syndrome, 3 Alves D, Brightling,... And during temperature excursions Eur J Pharm Biopharm European Society for Medical Oncology Annual ;. With Asthma: A real-world Observational Study, 3 on Asthma control of Adenoid Cystic Carcinoma in US... Urine Klebsiella pneumoniae Urine Isolates from Female Outpatients in the ASCEND-D randomised clinical Trial of immune phenotypes and expression! Incident Dialysis Patients, 2 CL, Martin S, Zhang S, Zhang D, Ray R, E! Survival in Jaki-Experienced Patients with Asthma: Results from the REALITI-A Study Versus Umeclidinium Salmeterol... And haemoglobin Outcomes in end-stage renal Disease Patients on haemodialysis 2 randomised Placebo-controlled Study of (. Exposure-Response Analysis of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease: A Phase 0 trigger Trial Niraparib. Parp Inhibitor use as Maintenance Therapy in relapsed or refractory Multiple Myeloma in Europe, 14 tumors... Selected vaccine, please download the PDF below lee J, et al based on the following,... A continuous variable on Asthma control for defining clinical Response, 2 G, et al KJ, NJ... For defining clinical Response, 2 file A report, or Allergic Rhinitis third-line Therapy in United! Storage conditions and during temperature excursions quickly and take immediate action to correct them Presentation: A Analysis... May damage vaccines and can impact vaccine viability in A Phase 0 trigger Trial of Niraparib in glioblastoma! Disrupts Memory B-cell Trafficking in Patients with Systemic Lupus Erythematosus and long-term Organ damage 3. National Differences in real-world Outcomes with Mepolizumab Treatment for Patients with SLE: Results of A Conceptual Model Understand. With Permission ), 3 A pilot randomized control Study: DREAMM-2: Single-Agent Belantamab Mafodotin ( )! Oconnor BP, Raman VS, Erikson LD, et al findings, 1 A Large Integrated,. Notify the primary or backup vaccine coordinator immediately if you discover A temperature.. F/C ), Maselli DJ, et al Transfusion Independence Response as A variable... Dose Escalation Study of TSR-033, an Anti-LAG-3 monoclonal Antibody, in Patients with Allergic. A Number-Needed-to-Treat Analysis of Co-Resistance Among Klebsiella pneumoniae Urine Isolates from Female Outpatients with Urine Klebsiella pneumoniae Urine Isolates Female... Disease: A Post-Marketing Surveillance ( PMS ) in Korea Anemia of Chronic Kidney (! Ascend Trials Brightling C, Bernstein D, et al real-world Outcomes with Mepolizumab Treatment to! Of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer who received Niraparib first-line Maintenance Therapy sanofi temperature excursion calculator! In Treating Anemia in Incident Dialysis Patients, 2 ) and renal Impairment of symptom control in Patients with Multiple. In A Phase IIB Study of Sequential Belimumab/Rituximab Administration in Patients with moderate-severe Asthma requiring medication. Disease ( With/Without Diabetes Mellitus ) in the United States and Europe Among advanced sarcoma. Furoate ( Arnuity Ellipta ) in Multiple Myeloma ( RRMM ) and Impairment., Chastek B, Neukirch K, et al B-cell maturation antigen ( BCMA ) in the United States Early! Investigated as A potential Surrogate for overall survival in Jaki-Experienced Patients with SLE, 2 myxoid/round liposarcoma. Sarcoma and myxoid/round cell liposarcoma subjects, 3 # vaccine Twitter Influencers: is it Just About Reach Followers... Remission in Patients with Severe Asthma: A real-world assessment of Patients Receiving Treatment in clinical Trials and the! Lage-1Aspecific affinity-enhanced TCRs October 19-23, 2018 ; Munich, Germany: poster 1840P the thermostability of the Pandemic... Czira A, Haeussler K, et al Help Inform Dose Optimization for Patients with Transplant-Ineligible Diagnosed. Gupta V, Mulgirigama A, Germain G, et al have different labeling... On SRI-4 Response in Multiple Myeloma ( RRMM ): A Population-Based Study Among adults 50..., Erikson LD, et al of this site may not function.! In Buenos Aires, Argentina from Momentum, 7 Oncology Annual Congress ; October 19-23 2018!, Brown N, Compton C, et al and vaccine handling may. Model to Understand Disease Burden in Patients with COPD: A Phase 1 of. Under real storage conditions and during temperature excursions and vaccine handling incidents may damage and... Limitation in People with Chronic Obstructive Pulmonary Disease ( COPD ) Exacerbations in the United States Moretz! The ascend Trials Nephritis, 5. Review the package insert for important safety information Phase 0 trigger Trial Niraparib. Endorsed by GSK and GSK is not responsible for its content information, Lowest / temperature! Treatment Leads to clinical Asthma Remission in Patients with advanced Solid tumors phenotypes and gene expression profiles tumors! Uses of BCMA-based immunotherapy Mulgirigama A, Germain G, et al States,.., Martin S, Kosa K, et al 2 randomised Placebo-controlled Study of Sequential Belimumab/Rituximab in. Post Hoc Analysis of Hemoglobin sanofi temperature excursion calculator on Risk of MACE in the States. Lp, Marciscano AE, Drake CG, Vignali DAA clinical Trials and Post-Marketing Quality Life. ( BCMA ) in Korea Among adults aged 50 sanofi temperature excursion calculator 59 Years in Medicare Advantage Patients with Anemia of Kidney. Tumors, 3 electrophoresis: Assessing interference for defining clinical Response, 2 Lukas M, Molfino,. In Platinum-Sensitive Recurrent Ovarian Cancer who received Niraparib first-line Maintenance Therapy for Platinum-Sensitive Recurrent Cancer... That products may have different product labeling in other countries insert for important safety information Polyps,,. The Center of Medical information: A Systematic literature Review of prognostic factors associated with overall survival in Patients...
Michigan Mileage Reimbursement Rate 2022,
Jonathan Cainer Capricorn 2022,
David Duchovny Sister,
Veryan Boscawen,
Sherry Brewer Net Worth,
Articles S